Cytosorbents Corporation (CTSO)
NASDAQ: CTSO · Real-Time Price · USD
6.85
-0.15 (-2.17%)
Sep 8, 2026, 4:00 PM EDT - Market closed
Cytosorbents Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 37.22 | 37.06 | 35.6 | 31.08 | 34.69 | 43.17 |
| 37.22 | 37.06 | 35.6 | 31.08 | 34.69 | 43.17 | |
Revenue Growth | 3.07% | 4.12% | 14.51% | -10.39% | -19.64% | 5.27% |
Cost of Revenue | 10.57 | 10.57 | 10.71 | 9.13 | 13.96 | 11.05 |
Gross Profit | 26.65 | 26.49 | 24.89 | 21.95 | 20.73 | 32.12 |
Selling, General & Admin | 33.78 | 35.65 | 33.73 | 38.31 | 36.5 | 38.48 |
Research & Development | 4.64 | 5.09 | 7.61 | 15.59 | 15.12 | 16.38 |
Operating Expenses | 38.42 | 40.73 | 41.34 | 53.9 | 51.62 | 54.86 |
Operating Income | -11.77 | -14.24 | -16.45 | -31.95 | -30.89 | -22.74 |
Interest Expense | -3.12 | -2.61 | -1.4 | -0.16 | - | - |
Interest & Investment Income | - | - | - | - | 0.13 | 0.03 |
Currency Exchange Gain (Loss) | -2.01 | 9.32 | -4.23 | 1.95 | -2.45 | -2.58 |
Other Non Operating Income (Expenses) | - | - | - | 0.1 | -0.07 | - |
EBT Excluding Unusual Items | -16.9 | -7.53 | -22.08 | -30.06 | -33.27 | -25.29 |
Merger & Restructuring Charges | -0.82 | -0.51 | - | - | - | - |
Asset Writedown | -0.9 | -0.56 | -0.33 | - | -0.64 | - |
Pretax Income | -18.62 | -8.6 | -22.41 | -30.06 | -33.91 | -25.29 |
Income Tax Expense | -0.4 | -0.4 | -1.69 | -0.81 | -1.09 | -0.74 |
Net Income | -18.21 | -8.2 | -20.72 | -29.25 | -32.81 | -24.56 |
Net Income to Common | -18.21 | -8.2 | -20.72 | -29.25 | -32.81 | -24.56 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 63 | 62 | 54 | 45 | 44 | 43 |
Shares Outstanding (Diluted) | 63 | 62 | 54 | 45 | 44 | 43 |
Shares Change | 8.00% | 14.32% | 21.90% | 2.49% | 0.49% | 11.70% |
EPS (Basic) | -0.29 | -0.13 | -0.38 | -0.65 | -0.75 | -0.57 |
EPS (Diluted) | -0.29 | -0.13 | -0.38 | -0.65 | -0.75 | -0.57 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -9.3 | -12.54 | -14.71 | -22.19 | -34.32 | -17.65 |
Free Cash Flow Per Share | -0.15 | -0.20 | -0.27 | -0.50 | -0.79 | -0.41 |
Gross Margin | 71.61% | 71.47% | 69.92% | 70.62% | 59.77% | 74.41% |
Operating Margin | -31.63% | -38.42% | -46.22% | -102.78% | -89.04% | -52.69% |
Profit Margin | -48.94% | -22.12% | -58.21% | -94.09% | -94.59% | -56.89% |
Free Cash Flow Margin | -24.98% | -33.84% | -41.33% | -71.39% | -98.94% | -40.88% |
EBITDA | -10.35 | -12.74 | -14.88 | -30.49 | -30 | -22.01 |
EBITDA Margin | -27.81% | -34.38% | -41.81% | -98.08% | -86.49% | -51.00% |
D&A For EBITDA | 1.42 | 1.5 | 1.57 | 1.46 | 0.88 | 0.73 |
EBIT | -11.77 | -14.24 | -16.45 | -31.95 | -30.89 | -22.74 |
EBIT Margin | -31.63% | -38.42% | -46.22% | -102.78% | -89.04% | -52.69% |
Revenue as Reported | - | - | - | - | 34.69 | 43.17 |
Advertising Expenses | - | 0.3 | 0.3 | - | 0.58 | 0.62 |